Our Drug Rebate Prediction Is Coming True: Now Can We Turn Our Attention to the Value of Drugs?

Posted by Pratap Khedkar on Tue, Feb 12, 2019

We predicted last year that prescription drug rebates’ days could be numbered as more healthcare stakeholders clamor for price transparency. Judging by the new rule proposed by Health and Human Services Secretary Alex Azar and Inspector General Daniel Levinson, this has now come to pass. The proposal aims to wipe out the behind-the-scenes negotiation tool—which has been linked to a growing discrepancy between a drug’s list and net prices—and instead share the savings directly with Medicare patients. 


>
Read More

Trump’s Drug Pricing Plan: What Does it Really Mean for Pharma?

Posted by Pratap Khedkar on Wed, Jul 04, 2018

Howard Deutsch co-authored this blog post with Pratap Khedkar.

President Donald Trump and HHS Secretary Alex Azar addressed the nation from the White House Rose Garden last week, introducing American Patients First, a drug pricing plan that Pres. Trump described as the “most sweeping action in history to lower the price of prescription drugs.” Let’s take a closer look, shall we?


>
Read More